Abstract
Short-term treatment with doxorubicin, cytarabine, and 6-thioguanine was given to 91 consecutive adults with acute myelogenous leukaemia. Fifty patients received high doses (regimen I) and 41 very high doses (regimen II). Where possible, six treatment cycles were given (total dose of doxorubicin 450 mg/m2) regardless of the number of cycles required to achieve complete remission. No additional treatment was given. The remission rate was significantly higher with regimen I than with regimen II (34/50 compared with 15/41, p less than 0.01), the latter, more intensive regimen being associated with a greater incidence of fatal infection (13/41 compared with 5/50, p less than 0.01). Duration of remission was, however, significantly longer with regimen II (p less than 0.05); the median has not yet been reached after a minimum follow-up of two years. Intensive short-term treatment is a feasible strategy for the treatment of acute myelogenous leukaemia.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Crowther D., Powles R. L., Bateman C. J., Beard M. E., Gauci C. L., Wrigley P. F., Malpas J. S., Fairley G. H., Scott R. B. Management of adult acute myelogenous leukaemia. Br Med J. 1973 Jan 20;1(5846):131–137. doi: 10.1136/bmj.1.5846.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gale R. P., Cline M. J. High remission-induction rate in acute myeloid leukaemia. Lancet. 1977 Mar 5;1(8010):497–499. doi: 10.1016/s0140-6736(77)91366-6. [DOI] [PubMed] [Google Scholar]
- Glucksberg H., Cheever M. A., Farewell V. T., Fefer A., Sale G. E., Thomas E. D. High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer. 1981 Sep 1;48(5):1073–1081. doi: 10.1002/1097-0142(19810901)48:5<1073::aid-cncr2820480504>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
- Lister T. A., Whitehouse J. M., Oliver R. T., Bell R., Johnson S. A., Wrigley P. F., Ford J. M., Cullen M. H., Gregory W., Paxton A. M. Chemotherapy and immunotherapy for acute myelogenous leukemia. Cancer. 1980 Nov 15;46(10):2142–2148. doi: 10.1002/1097-0142(19801115)46:10<2142::aid-cncr2820461005>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- McCredie K. B., Bodey G. P., Freireich E. J., Hester J. P., Rodriguez V., Keating M. J. Chemoimmunotherapy of adult acute leukemia. Cancer. 1981 Mar 15;47(6):1256–1261. doi: 10.1002/1097-0142(19810315)47:6<1256::aid-cncr2820470605>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powles R. L., Russell J., Lister T. A., Oliver T., Whitehouse J. M., Malpas J., Chapuis B., Crowther D., Alexander P. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer. 1977 Mar;35(3):265–272. doi: 10.1038/bjc.1977.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Preisler H. D., Bjornsson S., Henderson E. S. Adriamycin-cytosine arabinoside therapy for adult acute myelocytic leukemia. Cancer Treat Rep. 1977 Jan-Feb;61(1):89–92. [PubMed] [Google Scholar]
- Rees J. K., Sandler R. M., Challener J., Hayhoe F. G. Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT. Br J Cancer. 1977 Dec;36(6):770–776. doi: 10.1038/bjc.1977.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weinstein H. J., Mayer R. J., Rosenthal D. S., Camitta B. M., Coral F. S., Nathan D. G., Frei E., 3rd Treatment of acute myelogenous leukemia in children and adults. N Engl J Med. 1980 Aug 28;303(9):473–478. doi: 10.1056/NEJM198008283030901. [DOI] [PubMed] [Google Scholar]